Interferon signature gene expression is correlated with autoantibody profiles in patients with incomplete lupus syndromes

Clinical and Experimental Immunology

Volumn 159, Issue 3, 2010, Pages 281-291

  Li, Q Z ^a   Zhou, J ^a   Lian, Y ^a   Zhang, B ^a   Branch, V K ^b   Carr Johnson, F ^a   Karp, D R ^b   Mohan, C ^b   Wakeland, E K ^a   Olsen, N J ^a  

^a Division of Rheumatic Diseases   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Autoantibodies; Autoimmune disease; Gene expression profiling; IFN ; SLE

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M; INTERFERON;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; IMMUNOASSAY; LUPUS ERYTHEMATOSUS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; ANTIBODY FORMATION; AUTOANTIBODIES; AUTOANTIGENS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERFERONS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEOMICS; SOMATIC HYPERMUTATION, IMMUNOGLOBULIN;

EID: 74549204765     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2009.04057.x     Document Type: Article

References (30)

1. Goldblatt F, Isenberg DA. New therapies for systemic lupus erythematosus. Clin Exp Immunol 2005 140 : 205 212.
2. Chakravarty EF, Bush TM, Manzi S, Clarke AE, Ward MM. Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data. Arthritis Rheum 2007 56 : 2092 2094.
3. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982 25 : 1271 1277.
4. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997 40 : 1725.
5. Vila LM, Mayor AM, Valentin AH, Garcia-Soberal M, Vila S. Clinical outcome and predictors of disease evolution in patients with incomplete lupus erythematosus. Lupus 2000 9 : 110 115.
6. Swaak AJ, Van De BH, Smeenk RJ et al. Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT). Rheumatology (Oxf) 2001 40 : 89 94.
7. Gomez-Puerta JA, Martin H, Amigo MC et al. Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus? Medicine (Balt) 2005 84 : 225 230.
8. Fabio G, Carrabba M, Hu C, Floriani M, Besana C. Dramatic development of severe SLE in a patient with an incomplete disease. Rheumatol Int 2005 25 : 543 547.
9. Stahl HC, Nived O, Sturfelt G. Outcome of incomplete systemic lupus erythematosus after 10 years. Lupus 2004 13 : 85 8.
10. Baechler EC, Batliwalla FM, Karypis G et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003 100 : 2610 2615.
11. Bennett L, Palucka AK, Arce E et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003 197 : 711 723.
12. Wandstrat AE, Carr-Johnson F, Branch V et al. Autoantibody profiling to identify individuals at risk for systemic lupus erythematosus. J Autoimmunity 2006 27 : 153 160.
13. Li Q-Z, Zhou J, Wandstrat AE et al. Protein array profiles for insights into systemic lupus erythematosus and incomplete lupus syndromes. Clin Exp Immunol 2007 147 : 60 70.
14. Fossey SC, Vnencak-Jones CL, Olsen NJ et al. Identification of molecular biomarkers for multiple sclerosis. J Mol Diagn 2007 9 : 197 204.
15. Arbuckle MR, McClain MT, Rubertone MV et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003 349 : 1526 1533.
16. Wakeland EK, Liu K, Graham RR, Behrens TW. Delineating the genetic basis of systemic lupus erythematosus. Immunity 2001 15 : 397 408.
17. Giles I, Isenberg D. Lupus in the family - analysis of a cohort followed from 1978-1999. Lupus 2001 10 : 38 44.
18. Maas K, Chen H, Shyr Y, Olsen NJ, Aune T. Shared gene expression profiles in individuals with autoimmune disease and unaffected first-degree relatives of individuals with autoimmune disease. Hum Mol Genet 2005 14 : 1305 1314.
19. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991 121 : 293 298.
20. Li QZ, Xie C, Wu T et al. Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays. J Clin Invest 2005 115 : 3428 3439.
21. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005 52 : 1491 1503.
22. Nikpour M, Dempsey AA, Urowitz MB, Gladman DD, Barnes DA. Association of a gene expression profile from whole blood with disease activity in systemic lupus erythaematosus. Ann Rheum Dis 2008 67 : 1069 1075.
23. Bengtsson A, Sturfelt G, Truedsson L et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not antiretroviral antibodies. Lupus 2000 9 : 664 671.
24. Bave U, Vallin H, Alm GV, Ronnblom L. Activation of natural interferon-α- producing cells by apoptotic U937 cells combined with lupus IgG and its regulation by cytokines. J Autoimmun 2001 17 : 71 80.
25. Bave U, Nordmark G, Lovgren T et al. Activation of the type I interferon system in primary Sjögren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 2005 52 : 1185 1195.
26. Lovgren T, Eloranta ML, Bave U, Alm GV, Ronnblom L. Induction of interferon-α production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum 2004 50 : 1861 1872.
27. Eloranta ML, Helmers SB, Ulfgren AK, Ronnblom L, Alm GV, Lundberg IE. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum 2007 56 : 3112.
28. Kim D, Peck A, Santer D et al. Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis. Arthritis Rheum 2008 58 : 2163 2173.
29. Krippner H, Merle S, Jorgens K, Pirlet K. Antibodies to dsDNA and ssDNA in the immunoglobulin classes IgG and IgM: prognostic value in the course of SLE. Z Rheumatol 1984 43 : 265 271.
30. Le BA, Thompson C, Kamphuis E et al. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J Immunol 2006 176 : 2074 2078.